FDA Brief

Warning letters Drugs

FDA warning letter to

Woorilife & Health

High riskIssued Dec 28, 2023Posted Jan 9, 2024Center for Drug Evaluation and Research | CDER

Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

What happened

FDA reviewed records Woorilife & Health submitted after FDA's February 8, 2023, and July 12, 2023, requests under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act; this was a records review, not an inspection. FDA found the firm did not test each shipment of each lot of high-risk components, including glycerin, propylene glycol, and sorbitol solution, to verify identity and screen for diethylene glycol (DEG) or ethylene glycol (EG). FDA also found the quality unit did not effectively exercise its authority to approve or reject components.

What FDA found

  1. The firm did not perform at least one identity test on each incoming lot of high-risk components, including glycerin, propylene glycol, and sorbitol solution, using the USP test that detects diethylene glycol and ethylene glycol.

    21 CFR 211.84(d)(1)
  2. The quality unit did not adequately exercise its responsibility and authority to approve or reject components in the materials system.

    21 CFR 211.22(a)

What FDA wants

FDA asks the firm to respond in writing within 30 working days with a plan to correct the violations, including DEG/EG test results for retained high-risk component lots or implicated finished batches, a risk assessment for in-date products, customer notifications and recalls for contaminated lots, and improved component testing and quality-unit oversight. FDA also recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.

Who should pay attention

  • brands that buy OTC drugs or toothpaste from this contract manufacturer
  • drug makers using glycerin, propylene glycol, or sorbitol from high-risk suppliers
  • companies that rely on supplier certificates of analysis for incoming ingredient testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  4. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk